Compare Stocks

→ top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MRNA Moderna	$105.74 -2.9%	$101.85	$62.55 ▼ $142.79	$40.49B	1.62	4.09 million shs	1.86 million shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MRNA Moderna	+0.89%	+5.23%	-1.39%	+5.87%	-19.31%

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
MRNA Moderna	3.9759 of 5 stars	3.1	2.0	0.0	4.6	1.8	3.3	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MRNA Moderna	2.24	Hold	$126.49	19.62% Upside

Current Analyst Ratings

Latest MRNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/11/2024	MRNA Moderna	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold
4/9/2024	MRNA Moderna	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$125.00
4/1/2024	MRNA Moderna	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
3/28/2024	MRNA Moderna	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$125.00
3/28/2024	MRNA Moderna	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold
2/26/2024	MRNA Moderna	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Reduce	$75.00 ➝ $86.00
2/23/2024	MRNA Moderna	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$125.00
2/23/2024	MRNA Moderna	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$82.00 ➝ $91.00

(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MRNA Moderna	$6.75B	5.99	N/A	N/A	$36.33 per share	2.91

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MRNA Moderna	-$4.71B	-$12.41	N/A	N/A	N/A	-68.84%	-10.23%	-7.70%	5/2/2024 (Confirmed)

Latest MRNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/2/2024	N/A	MRNA Moderna	-$3.36	N/A	+$3.36	N/A	N/A	N/A
2/22/2024	Q4 2023	MRNA Moderna	-$0.78	$0.55	+$1.33	$0.55	$2.53 billion	$2.80 billion

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
MRNA Moderna	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MRNA Moderna	0.04	3.42	3.36

Ownership

Institutional Ownership

Company	Institutional Ownership
MRNA Moderna	75.33%

Insider Ownership

Company	Insider Ownership
MRNA Moderna	15.20%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
MRNA Moderna	5,600	382.88 million	322.77 million	Optionable

MRNA Headlines

Source	Headline
	Analysts Estimate Moderna (MRNA) to Report a Decline in Earnings: What to Look Out for zacks.com - April 25 at 11:05 AM
	Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Illinois Municipal Retirement Fund marketbeat.com - April 25 at 8:29 AM
	Moderna, Inc.: Moderna To Present Respiratory & Cytomegalovirus Research at the ESCMID Global Congress finanznachrichten.de - April 25 at 8:26 AM
	Moderna To Present Respiratory & Cytomegalovirus Research at the ESCMID Global Congress accesswire.com - April 25 at 7:00 AM
	Moderna (MRNA) to Release Earnings on Thursday americanbankingnews.com - April 25 at 3:42 AM
	Sycomore Asset Management Invests $4.67 Million in Moderna, Inc. (NASDAQ:MRNA) marketbeat.com - April 24 at 10:27 PM
	How mRNA Is Rewriting the Rules of Cancer Treatment scitechdaily.com - April 24 at 10:24 PM
	Moderna partners with OpenAI to supercharge mRNA research with genAI mmm-online.com - April 24 at 5:24 PM
	Moderna Stock Jumps On Collaboration With OpenAI: What's Going On? msn.com - April 24 at 12:24 PM
	Moderna and OpenAI in pact to fast-track drug development msn.com - April 24 at 12:24 PM
	Moderna and OpenAI Collaborate To Advance mRNA Medicine accesswire.com - April 24 at 8:00 AM
	Pfizer and BioNTech commence legal action against Moderna in UK court pharmaceutical-technology.com - April 24 at 7:23 AM
	Moderna enters contract with Brazil to supply 12.5 million Covid-19 vaccines as part of national vaccination campaign pharmabiz.com - April 24 at 2:22 AM
	South Dakota Investment Council Acquires 44,779 Shares of Moderna, Inc. (NASDAQ:MRNA) marketbeat.com - April 23 at 9:10 PM
	Moderna Faces Pfizer, BioNTech in London Patent Battle over Covid-19 Vaccines In Legal Showdown msn.com - April 23 at 4:22 PM
	Moderna Investors Should Beware Patent-Dispute Fallout seekingalpha.com - April 23 at 2:40 PM
	Moderna, Pfizer/BioNTech set for UK court clash over COVID jab patents medicalxpress.com - April 23 at 11:21 AM
	Moderna gets grant for vaccine composition for varicella zoster virus pharmaceutical-technology.com - April 23 at 11:21 AM
	This may hurt: English High Court set for Moderna and Pfizer/BioNTech Covid battle starting today msn.com - April 23 at 11:21 AM
	Pfizer vs Moderna battle over COVID vaccine patents begins in UK reuters.com - April 23 at 7:21 AM
	Moderna halts planned vaccine plant in Kenya independent.co.ug - April 22 at 6:53 PM
	Cwm LLC Has $11.77 Million Holdings in Moderna, Inc. (NASDAQ:MRNA) marketbeat.com - April 22 at 8:41 AM
	Moderna Announces Contract with Brazil to Supply 12.5 million COVID-19 Vaccines as Part of National Vaccination Campaign accesswire.com - April 22 at 7:00 AM
	Covid vaccine makers to clash in London over mRNA patent dispute ft.com - April 22 at 12:45 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Moderna

NASDAQ:MRNA

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial